Heart failure is a severe health problem that is characterized by   an increasing prevalence and economic cost. According to the American Heart Association, in the United States nearly one million new cases are reported each year.

BNP and NT-proBNP are established diagnostic and prognostic biomarkers of heart failure. The clinical values of these markers are  similar and both of them are used in clinical practice. Clinical guidelines recommend measuring either BNP or NT-proBNP in order to rule out heart failure in the initial assessment of a patient with suspected acute heart failure. Both markers can also be used to monitor the progression of the disease.

Products

We provide a broad range of well characterized monoclonal antibodies that allow for the development of sensitive and reliable immunoassays that are suitable for the detection of proBNP, NT-proBNP and BNP in clinical samples. We also provide different recombinant antigens that can be used as standards and calibrators in immunoassays.

For more information about the products and development of prototype immunoassays for BNP (conventional and SES-BNP™ assays) and NT-proBNP as well as of immunoassays detecting only full-length proBNP, please see our Human proBNP, BNP and NT-proBNP TechNotes here.

Cat# 4BNP2cc: BNP, human, antibody, in vitro
Cat# 4BNP2: BNP, human, antibody
Cat# 4NT1cc: NT-proBNP, human, antibody, in vitro
Cat# 4NT1: NT-proBNP, human, antibody
Cat# 4BFab5cc: Immune complex 24C5-BNP proBNP, antibody, in vitro
Cat# 4BFab5: Immune complex 24C5-BNP proBNP, antibody
Cat# 8NT2: NT-proBNP, recombinant, human
Cat# 8PRO9: proBNP, recombinant, human
Cat# 8GOB2: Human recombinant proBNP glycosylated
Cat# 8BFP: BNP and NT-proBNP Free Plasma

Research

At HyTest, we have been studying proBNP and its derivatives for several years and published several articles in peer reviewed journals. Check all our articles here.
Our researchers have presented posters about BNP, NT-proBNP and proBNP in several scientific conferences. Check all our posters here.